Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (July 2017)
41 slides from Optiscan Imaging's investor presentation, Jul 3, 2017
Slide 1: Optiscan Imaging Ltd – Global Leader in Live Micro Imaging
Confocal Endomicroscope Optiscan Imaging Ltd Global Leader in Live Micro Imaging Investor presentation - July 2017
Slide 2: Notice – Forward Looking Statements
Notice – Forward Looking Statements Confocal Endomicroscope Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, u
Slide 3: Optiscan Corporate Snapshot
Optiscan Corporate Snapshot Capital Structure Number of % of fully Notes Units diluted Ordinary Shares, ASX Code OIL (million) 376.1 93.7% Confocal Endomicroscope Unlisted Options (million) 25.5 6.3% Average exercise price $0.062 (6.2 cents) Average expiry date 30 June 2019 Fully Diluted Shares (mil
Slide 4: New Leadership Structure since 2016
New Leadership Structure since 2016 Confocal Endomicroscope • CEO Archie Fraser (ex Adecco, Inchcape, Cendant, St Kilda FC). • Chairman Alan Hoffman (ex Archie Fraser Alan Hoffman Shell, Wesfarmers, Coventry) • CTO Peter Delaney (Founder, Technology and Applications Specialist) • Strong focus on com
Slide 5: Value Added to Market Cap Since July 2016
Value Added to Market Cap Since July 2016 • Jul-16 $750k raised @2.5c Market Cap $6.3m Confocal Endomicroscope • Stock was suspended on ASX at 2.0c • Sep-16 $1.41m raised @2.5c Market Cap $9.0m • Stock lifted from suspension and relisted at 2.5c • Dec-16 $1.93m raised @5.0c Market Cap $22.8m • Apr-1
Slide 6: Who is Optiscan?
Who is Optiscan? • Global leader in live micro imaging through its unique patented Confocal Endomicroscope confocal laser endomicroscopy technology • Based in Melbourne, Australia • Trading on Australian Stock Exchange (ASX Code: OIL) • Over AUD$100m invested to date • Launched 2nd generation Precli
Slide 7: Optiscan is a Global Leader in its Field
Optiscan is a Global Leader in its Field Confocal Endomicroscope • Founded 1994, IPO on ASX 1997 • World’s first confocal laser endomicroscope (CLE), 2001 • Licensed to Pentax (Japan) in 2002, launched globally 2006 • Pentax user base remains in place although product now obsolete • Patented Point S
Slide 8: What is a Confocal Laser Endomicroscope?
What is a Confocal Laser Endomicroscope? Confocal Endomicroscope • “endo” = “inside”, so it is a microscope that can be used inside the living body • Miniaturised microscope on the end of a flexible single optical fibre • Utilises Confocal Technology • ‘Optical Sectioning’ ***add confocal image • Vi
Slide 9: Optical Sectioning Feature
Optical Sectioning Feature Confocal Endomicroscope Confocal Image Plane Investor presentation - July 2017
Slide 10: Surface to subsurface cellular imaging
Surface to subsurface cellular imaging Z-Stack Sequence 3D animation Confocal Endomicroscope Investor presentation - July 2017
Slide 11: What Competitors Don’t Want You to Know
What Competitors Don’t Want You to Know • The term “Endomicroscope” is used very broadly Confocal Endomicroscope • Nearest competitor offering based on fibre bundles: • 60 fold lower image information content • Lower resolution • Maximum 30,000 optical pixels (0.03 Megapixels), only a few thousand p
Slide 12: Carl Zeiss Meditec Partnership – Microsurgery
Carl Zeiss Meditec Partnership – Microsurgery • Esteemed in optical imaging • Market leader in neurosurgical visualisation Confocal Endomicroscope Investor presentation - July 2017
Slide 13: Partnership with Carl Zeiss Meditec
Partnership with Carl Zeiss Meditec • CZM FY16 revenue €1.09bn, EBIT €154m Confocal Endomicroscope • Major German optics company (Xetra: AFX), market cap €3.9bn • No. 1 global player in surgical microscopes through Pentero and other brands (Estimated CZM market share >60%) • Zeiss chose Optiscan’s t
Slide 14: Neurosurgery
Neurosurgery • Most critical surgical domain, where small surgical errors Confocal Endomicroscope can have significant life altering impact • The goal of surgery is to remove tumour, not brain • Biopsies are problematic - margins often appear vague • Real-time visualization with cellular detail crea
Slide 15: Optiscan’s technology extends the boundary of neurosurgical visualisation
Optiscan’s technology extends the boundary of neurosurgical visualisation • By adding Optiscan’s technology, the surgeon’s Confocal Endomicroscope armamentarium is extended to offer cellular detail • This is unprecedented and perfectly aligned with Zeiss’s mission Real-time microscopy provides the s
Slide 16: Video of live imaging
• Video of live imaging • Probe is moved across Confocal Endomicroscope tissue • Initially, tissue is normal • Then, an island for cancer cells (glioblastoma) is clearly observed • Finally, the surgeon moves between the two and finds the infiltrating margin of the tumour 0.5mm Investor presentation
Slide 17: Montage of images
Tumour: Glioblastoma. However, at upper Montage of images as the right, a clear island of surgeon moves the Optiscan TUMOUR large round Tumour probe over a small region of cells is seen, brain and Tumour. The Grey surrounded by a tissue at lower left is normal characteristic region of Confocal Endom
Slide 18: The Market Opportunity - Neurosurgery
The Market Opportunity - Neurosurgery Confocal Endomicroscope • Expected to be ~27,110 new brain cancer cases per annum in the US and 80,000 new tumour cases overall4 • There are ~700,000 people living with a brain tumour in the USA4 • Brain metastases tend to double the cost of cancer care2 • Five
Slide 19: Incidence according to type
Incidence according to type Overall incidence (new cases) of Primary Brain Tumour is Confocal Endomicroscope 14 per 100,000 people or ~49,000 new cases per year in the USA (malignant and benign). Meningiomas 36.6% 5 per 100,000 people Gliomas 24.7% 3 to 4cases per 100,000 Glioblastoma 14.9% 2 cases
Slide 20: Prevalence according to type
Prevalence according to type • Overall prevalence (all people living with a tumour) of Primary Brain Confocal Endomicroscope tumours is ~200 cases per 100,000 capita in the US1 (~700,000 people) Meningiomas 36.6% 73 per 100,000 • Optiscan’s technology is Gliomas 24.7% 49 per 100,000 applicable to: •
Slide 21: The New Zeiss/Optiscan Collaboration Device
The New Zeiss/Optiscan Collaboration Device Confocal Endomicroscope • Product development and early clinical work completed • 130 clinical cases performed and data published • Zeiss expects early uptake from key opinion leaders • Optiscan will manufacture the confocal microscope components for sale
Slide 22: The Market Opportunity – Neurosurgery Summary
The Market Opportunity – Neurosurgery Summary • Overall incidence of Primary Brain Tumour is 14 per 100,000 Confocal Endomicroscope • Overall prevalence of 700,000 brain tumour cases in 2017, we estimate approximately 240,000* surgical procedures per annum are eligible to benefit from Optiscan’s tec
Slide 23: Neurosurgery Systems Estimates
Neurosurgery Systems Estimates • In the USA there are ~5,000 major surgical facilities • In the USA there are ~1.15 million Neurosurgery procedures per annum • To cover the annual procedures volume in the USA @200 procedures per system, per Confocal Endomicroscope annum, estimated that 5,754 fully o
Slide 24: Global Surgical Procedure Volumes
Global Surgical Procedure Volumes* Confocal Endomicroscope * Excludes Gastrointestinal Endoscopy (not surgically invasive) Investor presentation - July 2017
Slide 25: Gastrointestinal (GI) Endoscopy
Gastrointestinal (GI) Endoscopy • GI endoscopy is considered outside of surgery (less invasive) Confocal Endomicroscope • Up to 14 million US procedures pa • 2002: Optiscan partnered with Pentax (Japan) • AUD$18M deal (3 equal components: up-front; license; equity) • Exclusive rights for flexible GI
Slide 26: Endoscopic Process and Medical Need
Endoscopic Process and Medical Need • Common endoscopic procedures involve 3 key steps: Confocal Endomicroscope 1. Detection of an area of interest 2. Characterisation (i.e. a closer look) 3. Confirmation – a firm cellular diagnosis • Multiple techniques have crowded into the first two steps, but on
Slide 27: Endomicroscopy Workflow
Endomicroscopy Workflow Optiscan’s endomicroscope Confocal Endomicroscope Conventional endoscopic view provides detection of scanner provides fast scanning areas of interest and initial and ultra-high definition “virtual characterisation biopsies” But which of these 1? sites contains an invisible bu
Slide 28: Barrett’s Oesophagus and Barrett’s Cancer
Barrett’s Oesophagus and Barrett’s Cancer Confocal Endomicroscope Site 1: Normal Barrett’s Oesophagus Site 2: Barrett’s carcinoma (early cancer) Images courtesy of Dr Ralf Kiesslich, Mainz University Hospital, Germany Investor presentation - July 2017
Slide 29: Barrett’s Oesophagus – a major opportunity
Barrett’s Oesophagus – a major opportunity • >20% of the US population complain of regular heartburn Confocal Endomicroscope • >10% will suffer chronic heartburn (~34m people) • Of these 10% will develop Barrett’s oesophagus, requiring endoscopic surveillance due to increased cancer risk • Sites of
Slide 30: Changing Clinical Practice (Barrett’s Oesophagus)
Changing Clinical Practice (Barrett’s Oesophagus) • GI User base has used the Optiscan-Pentax product to change clinical practice Confocal Endomicroscope • American Society for Gastrointestinal endoscopy (ASGE) funded landmark trial (see at left) • 2013 – results published in GIE (level 1 evidence)
Slide 31: GI Endomicroscopy
GI Endomicroscopy Confocal Endomicroscope • Largest market opportunity for Optiscan • Multiple clinical indications for use • 3 Category 1 CPT codes in place • Reimbursement in place • Optiscan offers compelling technical leadership • Highest level clinical results support Optiscan’s technology Inve
Slide 32: Platform Technology
• Platform Technology – applicable to any field of endoscopy/surgery • Strong clinical evidence already established in several fields Neurosurgery Brain 1.7% or 1.1M ENT procedures pa Confocal Endomicroscope (US) Esophagus Pancreas GI Endoscopy Stomach Airways (non- surgical) Small 14M bowel Pleura
Slide 33: Endomicroscope Overview
Confocal Confocal Endomicroscope Endomicroscope Optiscan’s next generation of incredible imaging capability and flexibility for Preclinical Research Investor presentation - July 2017
Slide 34: Preclinical Research
Preclinical Research Confocal Endomicroscope • Preclinical Research is where it all starts and is the proving ground for Clinical applications • Non-human use is the training ground for Clinical e.g. Neurosurgery • Optiscan started its life in Preclinical Research, and remains committed to the Precl
Slide 35: Preclinical Research Product
Overview Confocal Preclinical Research Product Confocal • Latest Generation Imaging Platform • Miniaturised Confocal Endomicroscope Endomicroscope • Low Laser Power – High Sensitivity Endomicroscope • Precise Optical Sectioning • For use in Preclinical Research (Animal Models) • Of Living Tissue wit
Slide 36: ViewnVivo B30 Configuration
ViewnVivo B30 Configuration C on Confocal Endomicroscope ocf a l E n d Image only o m ic oscr op e Investor presentation - July 2017
Slide 37: ViewnVivo Features
ViewnVivo Features Confocal Take Imaging to the Model Confocal • Flexibility • Stunning Image Quality • Enable In Vivo Imaging Endomicroscope • Move from Intravital to true In Vivo Endomicroscope • Enable Longitudinal Studies • Reduced terminal outcomes ((of animal model) • Small Space Requirement a
Slide 38: Dog Stomach
C on Confocal Endomicroscope ocf a l E n d Image only o m ic oscr op Dog Stomach e Image courtesy of Researchers at the University of Melbourne, Faculty of Veterinary and Agricultural Sciences
Slide 39: Enabling Real-time Research
Enabling Real-time Research Whole Mount Visceral Adipose Tissue Confocal Endomicroscope Field of view – 475um across Images courtesy of Enyuan Cao Investor presentation - July 2017 Monash Institute of Pharmaceutical Sciences
Slide 40: ViewnVivo Drives CLE Adoption in Research
ViewnVivo Drives CLE Adoption in Research Confocal Endomicroscope • ViewnVivo is Optiscan’s CLE device for Preclinical Research • Launched in late 2016 • Same underlying imaging technology as that used in CZM collaboration • Current ViewnVivo product is being well received by Researchers globally •
Slide 41: Thank You
Confocal Endomicroscope Thank You Archie Fraser Chief Executive Officer Optiscan Imaging Limited (ASX: OIL) Em: afraser@optiscan.com Mb: +61 411 151 515 Investor presentation - July 2017